Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
Posted on: Monday, 8 October 2007, 15:00 CDT
SAN DIEGO, Oct. 8 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company will present its research entitled: Generational Association Studies of Dopaminergic Genes (DRD1, DRD2, DAT1, & DBH) In Reward Deficiency Syndrome (RDS): A Paradigm Shift In Selecting Appropriate Phenotypes For Reward Dependence Behaviors at the XVth World Congress on Psychiatric Genetics October 7 - 11, 2007 in New York City, NY.
Dr. Kenneth Blum, Chief Scientific Officer of Salugen will discuss the generational association of genes associated with Reward Deficiency Syndrome (RDS). Numerous studies have revealed an association between certain dopaminergic gene polymorphisms and a number of reward dependent behaviors including addictive, compulsive and impulsive tendencies. These interrelated reward-dependent behaviors involving dopaminergic genes have been classified as RDS.
Additionally, he will present findings corresponding to multi-factorial phenotypes associated with the genes including ADHA, alcoholism, cocaine dependence, intravenous drug dependence, carbohydrate binging, smoking, hyperactivity, sex addiction, pathological violence, Tourette Syndrome, autism, and other personality disorders in an experimental group of 55 subjects derived from up to five generations of two independent multiple- affected families.
Salugen CEO Brian Meshkin states, "We are pleased to present Salugen's continued research on RDS. These findings aid us in furthering the clinical application of the research to assist those with a genetic predisposition to conditions associated with RDS."
Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (http://www.genotrim.com/), SpaGen(TM) for optimal health and wellness (http://www.spagen.com/) and Haveos(TM) for substance abuse attenuation.
About Salugen
Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit http://www.salugen.com/.
Salugen, Inc.
CONTACT: Salugen, Inc., +1-858-535-4825, or fax, +1-858-535-4890
Web site: http://www.salugen.com/
Source: PRNewswire
Related Articles
- Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant and Sustained Improvement in Diarrhea-Associated Irritable Bowel Syndrome (D-IBS)
- Researchers at Pulmonary Associates to Study Airway Bypass Procedure for Severe Emphysema
- Norditropin(R) Approved for Treatment of Children With Short Stature Associated With Turner Syndrome
- Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
- AMR Research and National Association of Manufacturers Reveal That 25% of U.S. Manufacturers Will Shift a Third of Production Overseas If Conditions Persist
- Insmed Releases Positive Results From IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
- Diabetes Gene at Root of Wider Syndrome
- Serono Completes Second Phase III Trial of Its Proprietary Recombinant Human Growth Hormone for HIV-Associated Adipose Redistribution Syndrome (HARS)
- Induction of B7-1 in Podocytes is Associated With Nephrotic Syndrome
 |
 |
User Comments (0)
RSS Feeds